Prostate Specific Antigen | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its Prostate Specific Antigen coverage policy, effective May 15, 2026. Here's what billing teams need to do before that date.

CMS's prostate specific antigen coverage policy governs Medicare reimbursement for PSA testing—one of the most commonly billed preventive screening labs in primary care and urology. This modification affects how you document, code, and bill PSA tests for Medicare beneficiaries. The policy does not carry a numbered policy code in the standard NCD or LCD format, but the change is tracked internally as a Modified coverage policy effective May 15, 2026. The specific CPT and HCPCS codes governing PSA billing are not listed in the current policy data—more on that below.

Quick-Reference Table

CMS Prostate Specific Antigen Coverage Criteria and Medical Necessity Requirements 2026

The CMS prostate specific antigen coverage policy has a long history. It sits at the intersection of preventive screening benefits and diagnostic testing—two billing categories that follow different rules under Medicare, and mixing them up is one of the most common sources of claim denial in this space.

Under Medicare, PSA testing has historically fallen into two buckets. The first is the annual prostate cancer screening benefit for Medicare beneficiaries. The second is diagnostic PSA testing ordered to evaluate a specific clinical concern. These two categories carry different billing requirements, different reimbursement rates, and different medical necessity documentation expectations.

CMS has modified this coverage policy effective May 15, 2026. Because the published policy data does not include the specific criteria text for this version, we cannot quote the exact updated language here. What we can tell you is that any modification to this policy warrants a close look at how your team separates screening PSA claims from diagnostic PSA claims—because that distinction is where most claim denials originate.

If you're billing PSA tests under Medicare and haven't reviewed your documentation templates recently, do it now. Medical necessity documentation for diagnostic PSA testing must reflect a clear clinical indication. Screening claims must align with Medicare's preventive benefit rules, including the frequency limitations that govern how often Medicare covers this test.

Prior authorization is not typically required for PSA testing under Medicare's screening benefit. However, diagnostic PSA testing in certain clinical contexts may draw scrutiny during post-payment review, particularly when frequency exceeds what CMS considers reasonable for monitoring. Your billing team should know which scenario applies to each claim before it goes out.

Talk to your compliance officer if you're unsure how this modification changes your specific documentation requirements. The effective date of May 15, 2026 gives you a defined window to get your house in order.

CMS Prostate Specific Antigen Exclusions and Non-Covered Indications

The policy data for this modification does not include a detailed list of excluded indications. However, based on CMS's long-standing approach to PSA coverage, certain situations consistently result in denied claims.

PSA testing billed more frequently than Medicare's screening benefit allows—currently one test per year for male beneficiaries age 50 and older—will not be reimbursed under the screening benefit. If additional testing is medically necessary, you must bill it as diagnostic and support it with documentation that clearly justifies the frequency.

PSA testing billed for beneficiaries who don't meet the age and sex eligibility criteria for the screening benefit also draws denials. This sounds obvious, but it creates real problems in practices where standing orders or EHR-generated lab requisitions aren't filtered by payer benefit rules.

Reflex PSA testing—where PSA is added to a panel without a specific physician order or documented clinical rationale—is another common denial trigger. Every PSA claim billed to Medicare needs a clear order and a clear reason.

Coverage Indications at a Glance

Because the specific updated criteria text is not available in the current policy data, this table reflects CMS's established PSA coverage framework. Review the full updated policy at the CMS source before the May 15, 2026 effective date.

CMS Prostate Specific Antigen Billing Guidelines and Action Items 2026

Here's what your team needs to do before May 15, 2026.

CPT, HCPCS, and ICD-10 Codes for Prostate Specific Antigen Under This Policy

The policy data for this modification does not list specific CPT, HCPCS, or ICD-10 codes. This is a meaningful gap. PSA billing guidelines typically reference specific lab codes, and the absence of code-level data in the published policy record means your team needs to go to the CMS source directly to confirm which codes are explicitly addressed.

What We Know About PSA Coding Under Medicare

We will not invent codes here. What we can tell you is that prostate specific antigen testing billing under Medicare involves lab procedure codes that distinguish between the screening benefit and diagnostic testing. Those codes carry different reimbursement implications, and billing the wrong code for the wrong benefit category is a guaranteed path to a claim denial.

Pull the current CMS fee schedule for clinical laboratory services and cross-reference it against your charge master. Confirm that every PSA-related code in your system is mapped to the correct benefit category and the correct diagnosis code range.

Action on Codes

Review the full policy at the CMS source linked in the policy record. If this modification adds, removes, or reclassifies any specific codes, you need that information before May 15, 2026. Update your charge capture accordingly.

If your billing system uses code-level edits to enforce coverage rules, update those edits to reflect any code changes in this modification. Don't wait for a denial to tell you that a code's coverage status changed.